EMEA-001164-PIP01-11-M06
Key facts
Invented name |
Veyvondi
|
Active substance |
vonicog alfa
|
Therapeutic area |
Haematology-Hemostaseology
|
Decision number |
P/0363/2022
|
PIP number |
EMEA-001164-PIP01-11-M06
|
Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
Condition(s) / indication(s) |
Treatment of von Willebrand disease
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Baxalta Innovations GmbH
Tel. +800 6683 8470
|
Decision type |
PM: decision on the application for modification of an agreed PIP
|